Related Experiment Video

Updated: Jul 21, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity

Christopher Cluxton1,2, Jarushka Naidoo1,2,3

  • 1Beaumont Hospital, RCSI Cancer Centre, D09 V2N0 Dublin, Ireland.

Current Oncology (Toronto, Ont.)
|July 28, 2023
PubMed

Insights

Immune checkpoint inhibitors (ICIs) offer durable anti-tumour responses but increase immune-related adverse events (IrAEs). This review examines clinical trials to establish evidence-based guidelines for managing ICI toxicities.

Area of Science:

  • Oncology
  • Immunology
  • Clinical Pharmacology

Background:

  • Immune checkpoint inhibitors (ICIs) are effective cancer therapies, inducing durable responses across many malignancies.
  • The widespread use of ICIs has led to an increase in immune-related adverse events (IrAEs).
  • Current IrAE management guidelines lack robust evidence, relying on retrospective data and case series.

Purpose of the Study:

  • To review the current clinical trial landscape for managing IrAEs.
  • To identify opportunities for developing standardized, evidence-based management algorithms for ICI-related toxicities.

Main Methods:

  • Systematic review of clinical trials investigating the management of immune-related adverse events.
  • Analysis of existing literature and guidelines for ICI-induced toxicities.

Main Results:

  • The current management of IrAEs is primarily based on limited evidence from retrospective studies.
  • There is a need for prospective, randomized controlled trials to establish definitive management strategies.
  • Clinical trials are emerging to address the need for standardized IrAE management.

Conclusions:

  • Standardized, randomized controlled trial-based management algorithms are crucial for optimizing the safety and efficacy of ICIs.
  • Further research and clinical trials are essential to refine IrAE treatment protocols.
  • Evidence-based guidelines will improve patient outcomes and facilitate wider adoption of ICI therapy.
Keywords:
adverse effectscancer immunotherapyclinical trialstumour immunology

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558